Our investment strategy focuses on hard tech sectors, including biopharma, advanced manufacturing, AI, semiconductors, and IT, targeting high-growth opportunities in strategic emerging industries. We actively support technology companies through direct investments, with successful exits including Jitucell Bio, Cigu Tech, Molight Optics, and Jingsheng Equipment (all listed on China's STAR Market), Quanxin Biotech (HKEX), and upcoming IPOs such as Huashuo Tech and Hansung Tech.